Document Detail

Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
MedLine Citation:
PMID:  22180549     Owner:  NLM     Status:  In-Data-Review    
Purpose The use of levocarnitine for the treatment of valproic-acid-induced hyperammonemic encephalopathy (VHE) is reviewed. Summary VHE is generally characterized by an acute onset of impaired consciousness, focal neurologic symptoms, and increased seizure frequency. The exact mechanism of VHE is unclear but relates to the accumulation of toxic valproic acid metabolites and elevated ammonia levels. Carnitine is an essential cofactor in the proper metabolism of valproic acid and ammonia elimination. A lack of carnitine is thought to contribute to hyperammonemia. Valproic acid is thought to increase renal metabolism of glutamate and may contribute to ammonia production. Levocarnitine, the active isomer of carnitine, has been used to treat VHE resulting from valproic acid overdose as well as usual dosages of valproic acid. A literature search of PubMed was conducted for all English-language articles published from 1948 to May 2011 regarding the use of levocarnitine for VHE. Search terms included levocarnitine, l-carnitine, valproic acid, and hyperammonemia encephalopathy. Although large, randomized controlled trials of levocarnitine treatment in VHE are lacking, levocarnitine has been shown to be generally safe and effective in retrospective trials and case reports. Overall, there is more literature supporting the use of levocarnitine in VHE associated with acute overdose than with short- or long-term treatment with usual dosages of valproic acid. No adverse events related to levocarnitine therapy were reported in any of the literature reviewed. Prospective trials are needed to further support the efficacy and safety of levocarnitine in the treatment of VHE. Conclusion Levocarnitine may be effective and appears to be safe in the treatment of VHE.
Christie M Mock; Kristen H Schwetschenau
Related Documents :
1820059 - Serine proteinase-catalyzed incorporation of d-amino into model peptides in acetonitril...
19502729 - Glutamyl trna synthetases and glutamic acid induce sexual differentiation of schizosacc...
22180549 - Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy.
7783229 - Evolution of the aminoacyl-trna synthetases and the origin of the genetic code.
22591159 - Cys34 adducts of reactive oxygen species in human serum albumin.
22332059 - Dietary triacylglycerol structure and its role in infant nutrition.
15508629 - Occurrence of listeria monocytogenes in green table olives.
18199999 - Ethyl-eicosapentaenoic acid in first-episode psychosis. a 1h-mrs study.
11416029 - Enhanced activity in parathyroid hormone-(1-14) and -(1-11): novel peptides for probing...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists     Volume:  69     ISSN:  1535-2900     ISO Abbreviation:  Am J Health Syst Pharm     Publication Date:  2012 Jan 
Date Detail:
Created Date:  2011-12-19     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9503023     Medline TA:  Am J Health Syst Pharm     Country:  United States    
Other Details:
Languages:  eng     Pagination:  35-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Telaprevir: An oral protease inhibitor for hepatitis C virus infection.
Next Document:  Anaphylactoid reaction to paliperidone palmitate extended-release injectable suspension in a patient...